Open AccessSecretion of Recombinant Interleukin-22 by Engineered Lactobacillus reuteri Reduces Fatty Liver Disease in a Mouse Model of Diet-Induced Obesity
Author(s) -
JeeHwan Oh,
Kathryn L. Schueler,
Donnie S. Stapleton,
Laura M. Alexander,
ChiLiang Eric Yen,
Mark P. Keller,
Alan D. Attie,
JanPeter van Pijkeren
Publication year - 2020
Publication title -
msphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.749
H-Index - 39
ISSN - 2379-5042
DOI - 10.1128/msphere.00183-20
Subject(s) - lactobacillus reuteri , nonalcoholic fatty liver disease , probiotic , fatty liver , steatosis , obesity , medicine , disease , liver disease , immunology , biology , bacteria , genetics
In humans, nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease due to the increased prevalence of obesity. While treatment of NAFLD is often geared toward lifestyle changes, such as diet and exercise, the use of dietary supplements such as probiotics is underinvestigated. Here, we report that probiotic Lactobacillus reuteri reduces fatty liver in a mouse model of diet-induced obesity. This phenotype was further enhanced upon delivery of recombinant interleukin-22 by engineered Lactobacillus reuteri . These observations pave the road to a better understanding of probiotic mechanisms driving the reduction of diet-induced steatosis and to development of next-generation probiotics for use in the clinic. Ultimately, these studies may lead to rational selection of (engineered) probiotics to ameliorate fatty liver disease.